UK-based company Synairgen has completed the recruitment of 120 subjects in its Phase II trial of an inhaled formulation of interferon-beta-1a (SNG001) for treating ‘at risk’ Covid-19 patients in the home setting.
The company’s two-part, placebo-controlled Covid-19 Phase II study (SG016) will evaluate SNG001 as a treatment for Covid-19.
One part involved the dosing of 101 patients in the hospital setting and positive results of the trial were published in The Lancet Respiratory Medicine last November.
Another part is the latest trial, which has completed the enrolment of 120 ‘at risk’ patients in the home setting.
The study is aimed at Covid-19 patients aged over 65 and those over 50 with ‘high risk’ medical conditions.
All supplies needed for the trial were courier-delivered to the patient’s door and all trial evaluations carried out by study doctors and nurses remotely through video call.
The trial was conducted in partnership with the NIHR Southampton Clinical Trials Unit and TranScrip Partners.
Synairgen CEO Richard Marsden said: “We are pleased to have completed recruitment of 120 ‘at risk’ patients into this innovative placebo-controlled trial whereby all trial ‘visits’ were conducted by video call.
“The trial is both a test of the drug, and a test of how technology can be utilised to deliver and manage the administration of an inhaled broad-spectrum antiviral to vulnerable patients in the context of a pandemic, reducing the need to transport infected patients, and eliminating virus exposure to healthcare workers.”
The company noted that the results from the trial are anticipated in the second quarter of this year.
Last July, Synairgen reported positive results from a clinical trial of its inhaled interferon beta candidate, SNG001, for the treatment of hospitalised patients with Covid-19.